CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Elacestrant

艾拉司群 杂质对照品Elacestrant Impurities

25 个杂质条目25 impurity entries

本页汇总 艾拉司群 的 25 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 25 impurity reference standards of Elacestrant. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisGram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones
    Chemical science · 2025 · Zong Y et al.  ·  PMID 41050573  ·  DOI

艾拉司群 —— 原料药与杂质对照品Elacestrant — drug substance & impurities

共 25 个条目(含原料药本体)25 items incl. the drug substance
N-Benzyl-N,N-dimethyl-1-phenylmethanaminium chloride structure
—
N-苄基-N,N-二甲基-1-苯基甲氯化铵N-Benzyl-N,N-dimethyl-1-phenylmethanaminium chloride
N-Benzyl-N,N-dimethyl-1-phenylmethanaminium chloride
CAS No.100-94-7
Chemical FormulaC16H20ClN
Purity>95%现货In stock
10mg25mg50mg100mg
Elacestrant Impurity 1 structure
1
艾拉司群杂质1Elacestrant Impurity 1
Elacestrant Impurity 1
CAS No.141606-35-1
Chemical FormulaC15H17NO
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 2 structure
2
艾拉司群杂质2Elacestrant Impurity 2
Elacestrant Impurity 2
CAS No.58196-33-1
Chemical FormulaC9H11NO
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 4 structure
4
艾拉司群杂质4Elacestrant Impurity 4
Elacestrant Impurity 4
CAS No.1030846-42-4
Chemical FormulaC27H29FN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 5 structure
5
艾拉司群杂质5Elacestrant Impurity 5
Elacestrant Impurity 5
CAS No.1078-19-9
Chemical FormulaC11H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 6 structure
6
艾拉司群杂质6Elacestrant Impurity 6
Elacestrant Impurity 6
CAS No.3470-50-6
Chemical FormulaC10H10O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 7 structure
7
艾拉司群杂质7Elacestrant Impurity 7
Elacestrant Impurity 7
CAS No.32263-70-0
Chemical FormulaC17H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 8 structure
8
艾拉司群杂质8Elacestrant Impurity 8
Elacestrant Impurity 8
CAS No.32263-71-1
Chemical FormulaC17H15BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 9 structure
9
艾拉司群杂质9Elacestrant Impurity 9
Elacestrant Impurity 9
CAS No.722536-74-5
Chemical FormulaC17H17BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 10 structure
10
艾拉司群杂质10Elacestrant Impurity 10
Elacestrant Impurity 10
CAS No.722536-73-4
Chemical FormulaC17H15BrO
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 11 structure
11
艾拉司群杂质11Elacestrant Impurity 11
Elacestrant Impurity 11
CAS No.5344-78-5
Chemical FormulaC7H6BrNO3
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 12 structure
12
艾拉司群杂质12Elacestrant Impurity 12
Elacestrant Impurity 12
CAS No.722536-75-6
Chemical FormulaC24H21NO4
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 13 structure
13
艾拉司群杂质13Elacestrant Impurity 13
Elacestrant Impurity 13
CAS No.722520-36-7
Chemical FormulaC17H19NO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 14 structure
14
艾拉司群杂质14Elacestrant Impurity 14
Elacestrant Impurity 14
CAS No.722520-42-5
Chemical FormulaC19H23NO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 15 structure
15
艾拉司群杂质15Elacestrant Impurity 15
Elacestrant Impurity 15
CAS No.722520-44-7
Chemical FormulaC24H31NO3
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 16 structure
16
艾拉司群杂质16Elacestrant Impurity 16
Elacestrant Impurity 16
CAS No.722535-39-9
Chemical FormulaC24H31NO3
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 17 structure
17
艾拉司群杂质17Elacestrant Impurity 17
Elacestrant Impurity 17
CAS No.722533-18-8
Chemical FormulaC33H39NO5
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 20 structure
20
艾拉司群杂质20Elacestrant Impurity 20
Elacestrant Impurity 20
CAS No.885280-42-2
Chemical FormulaC17H16O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 21 structure
21
艾拉司群杂质21Elacestrant Impurity 21
Elacestrant Impurity 21
CAS No.137494-04-3
Chemical FormulaC10H10O3
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 22 structure
22
艾拉司群杂质22Elacestrant Impurity 22
Elacestrant Impurity 22
CAS No.2309762-29-4
Chemical FormulaC30H38N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 22 Dihydrochloride structure
22
艾拉司群杂质22 双盐酸盐Elacestrant Impurity 22 Dihydrochloride
Elacestrant Impurity 22 Dihydrochloride
CAS No.2309762-30-7
Chemical FormulaC30H38N2O2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 24 structure
24
艾拉司群杂质24Elacestrant Impurity 24
Elacestrant Impurity 24
CAS No.2477812-42-1
Chemical FormulaC11H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 25 structure
25
艾拉司群杂质25Elacestrant Impurity 25
Elacestrant Impurity 25
CAS No.722533-24-6
Chemical FormulaC31H40N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 26 structure
26
艾拉司群杂质26Elacestrant Impurity 26
Elacestrant Impurity 26
CAS No.3033111-52-0
Chemical FormulaC19H23NO2
Purity>95%询价On request
10mg25mg50mg100mg
Elacestrant Impurity 29 structure
29
艾拉司群杂质29Elacestrant Impurity 29
Elacestrant Impurity 29
CAS No.2477812-39-6
Chemical FormulaC17H19NO2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

艾拉司群 —— 研究文献与合成路线Elacestrant — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 艾拉司群 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Elacestrant. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
    Bardia A, Kaklamani V, Wilks S, et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 被引 90cited 90
  2. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
    Bihani T, Patel HK, Arlt H, et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2017 · 被引 135cited 135
  3. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child
    Keenan JC, Medford AJ, Dai CS, et al. · Expert review of anticancer therapy · 2024 · 被引 8cited 8
  4. Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant
    Lu Y, Zhao Z, Wang S, et al. · European journal of medicinal chemistry · 2024 · 被引 2cited 2
  5. Molecular Modeling Studies of Similar Molecules to Selective Estrogen Receptor Degrader Elacestrant as Inhibitors of SARS-COV-2
    Omotoso OD, Joshua FO, Oyebamiji AK, et al. · Cell biochemistry and biophysics · 2025 · 被引 1cited 1
  6. Correction : Molecular Modeling Studies of Similar Molecules to Selective Estrogen Receptor Degrader Elacestrant as Inhibitors of SARS-COV-2
    Omotoso OD, Joshua FO, Oyebamiji AK, et al. · Cell biochemistry and biophysics · 2025

合成路线文献Synthetic-route papers

  1. Gram-scale synthesis of (+)-elacestrant streamlined by iridium-catalyzed dynamic kinetic asymmetric hydrogenation of α-substituted tetralones
    Zong Y, Zou X, Zhang S, et al. · Chemical science · 2025

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

艾拉司群 杂质谱研究要点Elacestrant — impurity profiling notes

下面这些是拿到 艾拉司群 的 25 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 25 impurity entries for Elacestrant, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances